Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CET

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09:19a SANOFI : refund, promise to help Dengvaxia victims boost plunder case vs Aquino,..
09:17a Sanofi to pay $11.6bn for Bioverativ for haemophilia biz and commercial netwo..
09:17a SANOFI : works with TriNetX to optimise trial recruitment
09:15a First Independent Comparison of Pharma Companies` Efforts to Address Drug-res..
08:15a SANOFI : Sees Currency Effects Negatively Impacting 4Q Sales
01:51a Two Biotech M&A’s Total $20 Billion, Ignites Hope for More Deals
01/23 SANOFI : Availability of the Pre-quarterly Results Communication
01/23 SANOFI : refund strengthens Dengvaxia case -- VACC
01/23 SANOFI : draws blood
01/23 SENATE PROBERS : P3.5-billion Dengvaxia deal rushed
More news
News from SeekingAlpha
01/23 Ionis Pharmaceuticals Is Poised To Disrupt Biotech
01/23 Sanofi (SNY) To Acquire Bioverativ (BIVV) - Slideshow
01/23 Bioverativ's Shareholders Hit The Jackpot
01/23 YOUR DAILY PHARMA SCOOP : Omeros' OMS721, Celgene To Acquire Juno, BioCryst And ..
01/23 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 22, 2018
Financials (€)
Sales 2017 35 646 M
EBIT 2017 9 077 M
Net income 2017 7 820 M
Debt 2017 5 853 M
Yield 2017 4,25%
P/E ratio 2017 11,44
P/E ratio 2018 15,59
EV / Sales 2017 2,69x
EV / Sales 2018 2,65x
Capitalization 89 910 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 83,4 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-0.93%110 732
JOHNSON & JOHNSON5.47%397 981
NOVARTIS1.29%226 840
PFIZER1.99%220 129
ROCHE HOLDING LTD.-4.34%211 542
MERCK AND COMPANY8.90%167 050